- Biotechnology
- Wednesday, 24 Jun 2020
Philogen Received Combination Pack Approval for Nidlegy
Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, on Jan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination of the active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF). NidlegyTM is being developed as a neoadjuvant intralesional treatment for resectable Stage III melanoma patients and in locally advanced, not metastatic nonmelanoma skin cancers. NidlegyTM combination pack has now received confirmation of eligibility to the centralized procedure for submission of an application for a Union Marketing Authorisation under Article 3(1) - Indent 1 - Biotech medicinal product of Regulation (EC) No 726/2004.
"We are extremely pleased to record EMA's agreement to our strategy for the marketing of NidlegyTM as a combination pack that was considered by CHMP 'indispensable for public health reasons,'" commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.
Related Industry Updates
Antibiotic Resistance Market Size, Share, Trend & Growth Forecast to 2027
Dec 02, 2020
Cancer Vaccines Market To Surge in The Near Future with Rapid Revenue Growth Across Key Industries
Sep 18, 2020
Agricultural Biotechnology Market Effect Factors Analysis 2027 – Adama, Chemchina, Corteva, Evogene And Limagrain
Mar 16, 2021
Microbial Identification Methods Market is expected to reach US$ 8,164.74 million by 2030
Sep 25, 2023
Sartorius Stedim Biotech Group Grows by Double Digits in 2019; Strong Outlook for 2020
Jan 28, 2020
Single-Photon Emission Computed Tomography Market Set for Rapid Growth and Trend, by 2027
Dec 10, 2020
Europe Drug Modelling Software Market to Reflect Impressive Growth Rate by 2027
Dec 30, 2020
Follow us on
